Moderna loses bid to invalidate vaccine delivery patents, teeing up potential infringement lawsuit Vertex once again talks up a tiny trial with positive read-throughs, this time for a genetically driven approach to kidney disease Get ready for M&A: Large biopharma companies will have $1.7T in dealmaking firepower next year, analyst says Who's fierce in medtech? Submit your nominations now for 2021's Fierce 15 COVID-19 tracker: First omicron case detected in US Survey: Many employers rolling out vaccine mandates despite ongoing legal challenges Coffee, tea or vaccine? Smart mug maker Ember plots shift to pharma cold-chain tech Aclaris' experimental rheumatoid arthritis drug bolsters chemo in pancreatic cancer models Federal judge orders nationwide pause on CMS' COVID-19 vaccine mandate for healthcare workers Supreme Court justices grill HHS in lawsuit surrounding nearly 30% cut to 340B payments Freenome, Siemens join forces to develop blood test for breast cancer 'What it takes': Genentech's Rachelle Doody recalls 'great sadness' of Alzheimer's failures but sees a future of options for patients Sanofi aims to double vaccine sales by 2030, citing RSV and flu market expansion as key drivers Virtual Incision garners $46M after mini-robot makes surgical debut Featured Story | By Fraiser Kansteiner Moderna has suffered a blow in its patent feud with Arbutus Biopharma, exposing the mRNA specialist to a potential infringement suit on its megablockbuster COVID-19 vaccine. read more |
| |
|---|
|
|
| The PerkinElmer Lead Discovery Premium Biotech Bundle empowers you to find and understand trends and outliers in your data to ensure successful candidate selection. On the AWS Cloud, affordable, easy to deploy. Learn more. |
Top Stories By Ben Adams Vertex in October gained plaudits and criticism in equal measure when it released data showing a single patient in a trial of its diabetes cell therapy stopped needing insulin; this time around, it’s plugging another major breakthrough in a tiny test in kidney disease. read more By Angus Liu Merger and acquisition activity has been rather slow in the biopharma industry so far this year. But, by one team of analysts’ calculations, large drugmakers will have big piles of cash to deploy in 2022. read more By Conor Hale As we begin to enter the third year of the COVID-19 pandemic (yes, the third), there’s still work to be done and evermore opportunities for medtech companies to make substantial differences in every field of healthcare. So which companies will deliver? read more By Kevin Dunleavy,Emmy Lucas,Fraiser Kansteiner The U.S. reports its first omicron variant case. The White House was blocked from enforcing two mandates requiring U.S. employees to get vaccinated. Plus more. read more By Paige Minemyer While the Biden administration's vaccine mandate remains in legal limbo, a new survey suggests many employers are rolling out such requirements anyway. read more By Andrea Park Temperature-control technology maker Ember’s business runs hot and cold—literally. read more By Arlene Weintraub Scientists at Washington University discovered that by inhibiting a molecule called MK2, Aclaris Therapeutics’ experimental rheumatoid arthritis drug boosted the ability of chemo to kill pancreatic cancer cells. In mouse models of the disease, the combo shrank tumors and improved survival, they reported. read more By Dave Muoio Trump-appointed judges from Louisiana and Illinois who issued preliminary injunctions against the vaccination mandates this week agreed that the requirements will harm plaintiff states and are unlikely to hold up in court. read more By Robert King Supreme Court justices grilled key parts of HHS' arguments over its bid to keep a nearly 30% cut to Medicare drug reimbursements for 340B hospitals. read more By Andrea Park The humble mammogram may soon be getting a complementary new partner to boost breast cancer screening. read more By Annalee Armstrong Fierce Biotech profiles three women breaking barriers in Alzheimer's disease R&D at leading pharmaceutical companies. Today, Genentech's global head of neurodegeneration, Rachelle Doody. read more By Eric Sagonowsky While Sanofi hasn’t been at the forefront of global COVID-19 vaccination efforts, the company still has big growth expectations in the vaccines field. Already the world’s top flu shot player, Sanofi sees mRNA, pneumococcal vaccines and respiratory syncytial virus as three areas of opportunity going forward. read more By Conor Hale With a device weighing only two pounds, the company’s MIRA platform aims to shrink down the surgeon and place them inside the abdomen. read more | 